CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

5mo

CYTKPhase 2$5.6B

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Phase 2 Results Expected

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)• Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)60

Sep 15Estimated

00%

Competitive Landscape

0 competitors in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Drug Information

Target Indication

Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CYTK

Cytokinetics, Incorporated

Related Pipeline

Heart Failure

Heart Failure With Reduced Ejection Fraction

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)